We are very pleased to announce that we have completed treatment of all planned patients in our HB-001 open label study to test the safety and efficacy of the Alpha DaRT targeted alpha radiation therapy in recurrent Head & Neck Cancer after radiotherapy in Japan.
The preliminary results of this trial are highly encouraging. Going forward, HekaBio will continue our analysis in collaboration with our medical experts, and will work on submission for shonin marketing approval in consultation with Japanese authorities.
We are delighted to have reached this important milestone and will continue to dedicate ourselves to enabling patient access to this potentially lifesaving therapy.
Read the press release from Alpha Tau Medical from here